Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319872 · ClinicalTrials.gov registry record · Phase 1
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
A Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06319872: Recruiting Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration, sponsored by University of Rochester.
NCT06319872 is a Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 15 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06319872, a Phase 1 study of Alcohol Use Disorder and Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
Primary Outcome
Visual acuity testing will be performed by Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity with refractive correction when indicated under photopic and mesopic conditions. The test will be performed by an ophthalmic technician and will be used for research purpose only. The right eye should be tested first. When it becomes evident that no further meaningful readings can be made, the examiner should stop the test. The final visual acuity should be noted. Visual acuity is a range
Conditions Studied
Interventions
- DRUG Oral disulfiram
Study Locations (1)
New York
- Flaum Eye Institute, University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2029-05-19 |
| Phase | Phase 1 |
What NCT06319872 shows while recruiting
NCT06319872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Oral disulfiram is the first listed.
NCT06319872 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06319872 about?
NCT06319872 is a clinical study titled "The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration". Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram ...
What is the current status of trial NCT06319872?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-05-19. Estimated completion is 2029-05-19.
What conditions does trial NCT06319872 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Age-related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Retinal Dystrophies.
What interventions are being tested in trial NCT06319872?
The interventions under investigation include: Oral disulfiram (DRUG).
Who is sponsoring clinical trial NCT06319872?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319872 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06319872's enrollment target sits among peer trials
15 176th of 184 higher than 9 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin for Treatment of Alcohol Use Disorder
RECRUITING · Phase 1
-
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
RECRUITING · Phase 1
-
Environment and Alcohol: A Pilot Study
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
RECRUITING · Phase 1
-
Sex Differences in the Response to Abstinence From Alcohol.
RECRUITING · Phase 1
-
PT150 Drug for Use in Alcohol Use Disorder
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI